- Cat. No.
- A20250
AGI-25696
AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Methionine adenosyltransferase (MAT) inhibitors block production of the main methyl donor in cells. MAT enzymes combine methionine and ATP to form S-adenosylmethionine (SAM), the substrate of DNA, RNA, histone and protein methyltransferases. MAT1A is expressed mainly in the liver, whereas MAT2A supplies SAM in most other tissues and in tumor cells. In 2016, cancer cells lacking methylthioadenosine phosphorylase (MTAP) were shown to depend on MAT2A and protein arginine methyltransferase 5 (PRMT5). PF-9366 binds an allosteric site of MAT2A, as reported in 2017. AG-270, IDE397 and FIDAS-5 are further inhibitors that target the MAT2A isoform. The category also contains 3-TYP, an inhibitor of sirtuin 3 (SIRT3).
AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.
PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.
MAT2A inhibitor 2 is a methionine adenosyltransferase 2A (MAT2A) inhibitor.
MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (MATA2) inhibitor with an IC50 less than l00 nM.
AGI-24512 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-24512 blocks growth of MTAP-deleted cancer cells in vitro.
FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.
Synonyms: MAT2A-IN-9; GSK-4362676
IDE397 (GSK-4362676) is a potent and selective inhibitor of methionine adenosyltransferase 2A (MAT2A). It exhibits strong anti-tumor activity, particularly in patient-derived xenograft (PDX) models with MTAP (methylthioadenosine phosphorylase) deletion. By targeting MAT2A in MTAP-deficient tumors, IDE397 exploits a synthetic lethality approach, making it a promising candidate for precision oncology research.
AG-270 is a first-in-class, reversible, and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor. It functions as an allosteric and noncompetitive inhibitor, with an IC₅₀ of 14 nM. AG-270 is being explored for its therapeutic potential in cancers with MTAP deletions, where MAT2A inhibition leads to selective antitumor effects via disruption of methylation-dependent processes.
MAT2A inhibitor 6 is a selective inhibitor targeting methionine adenosyltransferase 2A (MAT2A) with an IC50 of 26 nM. This compound exhibits yellow fluorescence, allowing for the visualization of MAT2A activity in both in vitro and in vivo settings (λex = 430 nm, λem = 585 nm). MAT2A inhibitor 6 has demonstrated the ability to induce apoptosis and possesses significant anticancer properties, making it a valuable tool in cancer research applications.
Out of stock
All 3 sizes
FIDAS-3 is a potent inhibitor of methionine S-adenosyltransferase 2A (MAT2A), functioning primarily through competition with S-adenosylmethionine (SAM) for binding. With an IC50 value of 4.9 μM, FIDAS-3 effectively disrupts MAT2A activity, making it a valuable tool for investigating Wnt signaling pathways. This stilbene derivative exhibits notable anticancer properties, contributing to its relevance in cancer research applications.
ZS34 is a potent and selective inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 13.7 nM. This compound effectively suppresses the growth of methylthioadenosine phosphorylase (MTAP)-deficient cancer cells by inhibiting S-adenosylmethionine (SAM) synthesis, leading to decreased levels of symmetric dimethylarginine (SDMA) and the induction of DNA damage. In vivo studies demonstrate its antitumor efficacy in a HCT116 MTAP-/- xenograft mouse model, making ZS34 a valuable tool for research focused on MTAP-deficient cancers.
Out of stock
All 3 sizes
AGI-41998 is a selective inhibitor of methionine adenosyltransferase 2A (MAT2A) that displays potent inhibitory activity with an IC50 of 22 nM in HCT-116 MTAP-null cells. This compound effectively crosses the blood-brain barrier and demonstrates the ability to inhibit S-adenosyl methionine (SAM) synthesis, with an IC50 of 34 nM. AGI-41998 is valuable for studying SAM regulation in the central nervous system (CNS) as well as for investigating its role in the proliferation of colon cancer cells and tumor growth.
SCR-7952 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), exhibiting an IC50 value of 18.7 nM. This compound is utilized in anti-cancer research to elucidate the role of MAT2A in tumor metabolism and growth. SCR-7952 provides valuable insights into therapeutic strategies targeting methionine metabolism in cancer cells.
AGI-43192 is a selective inhibitor of methionine adenosyltransferase 2A (MAT2A) that exhibits limited blood-brain barrier penetration. It demonstrates potent inhibitory activity against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells, with IC50 values of 32 nM and 14 nM, respectively. Furthermore, AGI-43192 effectively inhibits the proliferation of HCT-116 cells and reduces tumor growth, making it a valuable tool for investigating SAM regulation in both the central nervous system (CNS) and colon cancer research applications.
AZ'9567 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), which plays a critical role in cellular metabolism and proliferation. This compound demonstrates significant antiproliferative effects against MTAP knockout HCT116 cells, with a pIC50 value of 8.9. AZ'9567 is a valuable tool for investigating the role of MAT2A in cancer biology and therapeutic development.
MAT2A Inhibitor 3 is a selective inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of less than 200 nM. This compound serves as a valuable tool for studying the role of MAT2A in cancer biology and therapeutic interventions. Its inhibition of MAT2A activity can help elucidate the metabolic pathways involved in tumorigenesis and potentially aid in the development of novel anticancer strategies.
MAT2A Inhibitor 4 is a selective inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2 (MAT2A). This compound interferes with methionine metabolism, leading to potential anti-cancer effects by disrupting cellular methylation processes. MAT2A Inhibitor 4 is primarily utilized in cancer research to explore therapeutic strategies and metabolic pathways associated with tumorigenesis.
MAT2A-IN-18 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), demonstrating an IC50 of ≤50 nM. This compound is instrumental in studies exploring the biochemical pathways associated with methionine metabolism and its implications in various diseases. Researchers may utilize MAT2A-IN-18 for investigating therapeutic interventions in cancer and other disorders where MAT2A plays a critical role.
Out of stock
All 3 sizes
MAT2A-IN-23 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), exhibiting an IC50 of 4 nM. This compound effectively inhibits S-adenosylmethionine (SAM) production in both HCT-116 (MTAP−/−) and wild-type cell lines, with IC50 values of 3 nM and 2 nM, respectively. Furthermore, MAT2A-IN-23 demonstrates selective inhibition of symmetric dimethylarginine (SDMA) in HCT-116 (MTAP−/−) cells, with an IC50 of 2 nM, while displaying minimal activity in wild-type cells. In cellular assays, it significantly reduces proliferation in HCT-116 (MTAP−/−) cells with an IC50 of 47 nM, making it a valuable tool for studying MAT2A-related biological processes and potential therapeutic applications.
Out of stock
All 3 sizes
MAT2A-IN-17 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of less than 100 nM. This compound is primarily used in cancer research to investigate the role of MAT2A in tumor metabolism and proliferation. Its application can aid in understanding therapeutic targets for malignancies characterized by dysregulated methionine metabolism.
Out of stock
All 3 sizes
MAT2A-IN-20 is a selective inhibitor of methionine adenosyltransferase 2A (MAT2A), demonstrating an IC50 of less than 50 nM. This compound also inhibits human UGT1A1 with an IC50 of 28.45 µM. MAT2A-IN-20 has shown promising antitumor activity in mouse models, making it a valuable tool for cancer research and investigations into metabolic pathways involving methionine metabolism.
Out of stock
All 3 sizes
MAT2A-IN-6 is a selective inhibitor of methionine adenosyltransferase 2A (MAT2A). Elevated MAT2A expression is associated with various malignancies, including gastric, colon, liver, and pancreatic cancers. This compound effectively diminishes the proliferation of MTAP-deficient cancer cells, making it a valuable tool for cancer research and therapeutic development, particularly in targeting tumors with MAT2A overexpression.
MAT2A-IN-7 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). Elevated expression of MAT2A has been associated with various tumors, including gastric, colon, liver, and pancreatic cancers. This compound effectively reduces the proliferative activity of cancer cells lacking the MTAP gene, making it a valuable tool for cancer research and therapeutic development. MAT2A-IN-7 offers insights into the metabolic dependencies of tumors, particularly in the context of MAT2A overexpression.
MAT2A-IN-22 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 value of 4 nM. This compound is capable of penetrating the blood-brain barrier and demonstrates selective inhibitory effects on MTAP-deficient cancer cell lines. MAT2A-IN-22 exhibits notable anti-tumor activity, making it a valuable tool for cancer research and therapeutic development.
Out of stock
All 3 sizes